(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of 3.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Kymera Therapeutics's revenue in 2025 is $44,711,000.On average, 11 Wall Street analysts forecast KYMR's revenue for 2025 to be $6,134,636,818, with the lowest KYMR revenue forecast at $3,115,865,277, and the highest KYMR revenue forecast at $13,584,543,430. On average, 10 Wall Street analysts forecast KYMR's revenue for 2026 to be $3,578,025,744, with the lowest KYMR revenue forecast at $1,000,966,358, and the highest KYMR revenue forecast at $8,579,711,640.
In 2027, KYMR is forecast to generate $4,277,200,745 in revenue, with the lowest revenue forecast at $2,859,903,880 and the highest revenue forecast at $7,149,759,700.